Texas House of Representatives Human Services Committee to Host Public Hearing

Translate to Spanish or other 102 languages!

The public hearing will take place at the Edinburg Conference Center at Renaissance on August 29, 2018

Mega Doctor News

- Advertisement -

Edinburg, Texas ― The Texas House of Representatives Human Services Committee will host a public hearing at the Edinburg Conference Center at Renaissance in Edinburg, TX, on August 29, 2018, at 8:30 a.m. During the hearing members will review the history and future roll-out of Medicaid Managed Care in Texas. Members will examine the impact managed care has had on the quality and cost of health care throughout the state, and review initiatives that managed care organizations have implemented to improve the quality and care. Members will also investigate:

Whether access to care and if network adequacy contractual requirements are sufficient;
Provider and Medicaid participants’ satisfaction within STAR, STAR Health, Star Kids, and STAR+Plus managed care programs; and
The Health and Human Services Commission’s (HHSC) oversight of managed care organizations to make recommendations for any needed improvement.
Notice of Assistance at Public Meetings

Persons with disabilities who plan to attend this meeting and who may need assistance, such as a sign language interpreter, are requested to contact Stacey Nicchio at (512) 463-0850, 72 hours prior to the meeting so that appropriate arrangements can be made.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

American Cancer Society Updates Prostate Cancer Screening Guideline

The American Cancer Society (ACS) released an updated guideline for prostate cancer screening to help find cancer before it spreads and reduce the risk of dying from the disease.

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

Embolism Treatment Developed at University of Michigan receives FDA clearance 

Patients with persistent blood clots require frequent medical interventions just to survive. Yet despite this critical need, there have been few advancements in how these patients are treated. 

FDA Approves Once-Weekly Generic Hormone Therapy Patch for Women

The U.S. Food and Drug Administration approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA’s Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products.
- Advertisement -